Navigate Explained

Scientist in a lab coat holding a small vaccine vial beside a laptop with molecular graphics and an insulated carrier box
Researchers are testing whether AI can help design vaccines that do not need ultra-cold storage

Why Do Some Vaccines Need Deep Freezing?

Most vaccines are kept in refrigerators at +2°C to +8°C, according to the World Health Organization (WHO). Some mRNA COVID-19 vaccines are more fragile. UNICEF says they needed storage at minus 60°C to minus 80°C in ultra-cold freezers, which many countries did not have when the vaccines arrived. Installing that equipment also needs stable electricity and backup generators.

UNICEF reports it delivered more than 800 ultra-cold freezers to nearly 70 countries by the end of 2021, which shows how large the effort was. Standard cold chain capacity usually takes 12 to 18 months to build, UNICEF adds, and ultra-cold scale-up was far more complex. These storage needs make delivery harder in remote or low-resource areas. That is the problem a new study from the Massachusetts Institute of Technology (MIT) is trying to ease.

What Did the Researchers Do?

The study, published in Nature Biotechnology on September 28, 2026, was led by Ana Jaklenec and Robert Langer of MIT’s Koch Institute, with Jinbi Tian and Khanh Tran as lead authors. According to MIT News, the work was partly funded by the Gates Foundation.

mRNA vaccines are packed inside tiny fat bubbles called lipid nanoparticles. The team looked for ingredients, called excipients, that could protect the mRNA when it is stored. They screened nearly 50 excipients already approved by the US Food and Drug Administration, picked five, and then used an AI algorithm built to learn from very small amounts of data. The algorithm suggested ratios to test, the lab results were fed back in, and the cycle repeated. MIT says this took a few weeks, compared with months of manual testing that never reached full stability.

What Were the Results?

The vaccines carried COVID-19 mRNA and were dehydrated by vacuum drying. MIT reports they stayed stable at 37°C (98°F) for two months, or at room temperature for up to a year. In mice, immune responses were equivalent to those from a formulation similar to an existing mRNA vaccine, even after long storage. The team also made solid microneedle patches that produced an immune response similar to an injected RNA vaccine. The article does not name the animal used for the patch test.

Storage Approaches Compared

ApproachStorage conditionsStatus
Standard vaccines+2°C to +8°C (WHO)In routine use
Some mRNA COVID-19 vaccinesMinus 60°C to minus 80°C (UNICEF)Used during the pandemic roll-out
WHO controlled temperature chainOne exposure to at least 40°C for at least three days, just before useApproved only for specific licensed vaccines
MIT AI-designed formulation37°C for two months, or room temperature for one year (tested)Lab and mouse data only

What the Study Does Not Show

This is early research. MIT’s report describes lab and animal data only, with no human trials. It does not give the excipient names or ratios, and stability is reported only for the tested conditions. It also gives no timeline for clinical use. A Reuters report on October 7, 2026, summarised on MIT’s news-clip page, calls the approach “experimental.” The team says the algorithm could also stabilise a formulation similar to another approved mRNA vaccine, but the article gives no data for that.

Why It Could Matter

If the approach works in people, vaccines that tolerate warmer storage could be easier to ship and store, particularly where freezers and reliable power are scarce. Jaklenec said the strength of the algorithm is that it can work with small datasets. The researchers also say it could be used for other mRNA vaccines and drug-delivery systems. These are possibilities, not results.

How to Read Vaccine News Wisely

  1. Check the stage. Ask whether the result is from cells, animals or people.
  2. Read the original source. Look for the journal paper or the institution’s own announcement.
  3. Watch for exact conditions. “Stable at room temperature” depends on the time and temperature tested.
  4. Look for independent comment. Wait for experts who were not part of the study.
  5. Keep following your health authority. Nothing in this study changes current vaccine advice.

Frequently Asked Questions

Are there heat-proof mRNA vaccines available now?

No. The MIT work is experimental, and no human trials are reported.

What did the AI do?

It helped predict the best mix of storage-protecting ingredients from very small amounts of lab data, speeding up the search.

How long did the vaccines stay stable?

MIT reports two months at 37°C or up to one year at room temperature, in the conditions tested.

Does this change my vaccine advice?

No. Follow your doctor and national health authority.

Could this help other vaccines?

The researchers say the approach might apply to other mRNA vaccines, but that has not been shown yet.

The Bottom Line

MIT researchers used AI to design a dry mRNA vaccine formulation that stayed stable for months without deep freezing in lab and mouse tests. It is a promising early step, not a finished product, and human trials would be needed before it could be used.

Official Source Links

Sources

  • MIT News, “New formulation helps RNA vaccines withstand high temperatures,” September 28, 2026.
  • Tian J., Tran K., et al., “Accelerated discovery of thermostable mRNA–lipid nanoparticle vaccines using data-efficient AI,” Nature Biotechnology, September 28, 2026, as described by MIT News.
  • MIT News clip of Reuters, “Experimental approach uses AI to eliminate cold storage for mRNA vaccines,” October 7, 2026.
  • World Health Organization, “Controlled temperature chain (CTC).”
  • UNICEF, “Going ultra-cold: How UNICEF is supporting countries for COVID-19 vaccine roll-out.”

Editorial note: This is an independently written explainer based on publicly available information. It is not medical advice and does not endorse any vaccine product.

Comments

Could heat-stable vaccines change access to immunisation?

Easier storage could make a real difference in remote areas, but human trials come first. I would like to know what questions you have about this research.

Share your thoughts below, and please avoid posting personal or medical details.


Author: Atia Arefin | Published: October 12, 2026 | Last updated: October 12, 2026

Sources: MIT News (September 28, 2026), Nature Biotechnology, Reuters (October 7, 2026)

Image: Image created with Canva by Navigate Explained.

How we check and correct our articles: Editorial Policy. To report an error, contact us.

This article is for informational purposes only and is not medical advice. The research describes experimental vaccine formulations and does not mean that heat-tolerant vaccines are approved for routine human use.

Leave a Reply